Impact of the Donor KIR Genotype on the Clinical Outcome of Hematopoietic Stem Cell Unrelated Transplants: A Single Center Experience by Ingrassia, Francesco et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 7
Impact of the Donor KIR Genotype on the Clinical
Outcome of Hematopoietic Stem Cell Unrelated
Transplants: A Single Center Experience
Francesco Ingrassia, Valentina Cappuzzo,
Rosalba Bavetta, Serena Mistretta, Maria Igea Vega,
Paola Bruna Affaticati, Maria Blando,
Floriana Bruno, Emanuela Collura, Giovanna Regina,
Valentina Randazzo, Alessandro Indovina,
Felicia Farina and Raimondo Marcenò
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67047
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Francesco Ingrassia, Valentina Cappuzzo, 
Rosalba Bavetta, Serena Mistretta, 
Maria Igea Vega, Paola Bruna Affaticati, 
Maria Blando, Floriana Bruno, 
Emanuela Collura, Giovanna Regina, 
Valentina Randazzo, Alessandro Indovina, 
Felicia Farina and Raimondo Marcenò
Additional information is available at the end of the chapter
Abstract
In recent years, the anti-leukemic potential of Natural Killer (NK) cells and their role in 
hematologic malignancies and in Hematopoietic Stem Cell Transplants (HSCT) has attracted 
greater interest and a recent study by Cooley S. et al. showed a better clinical outcome when 
patients with Acute Myeloid Leukemia received a transplant from unrelated Group B KIR 
haplotypes donors. As a consequence of these results, an algorithm called “KIR B-content 
score” was formulated. The aim of our research is a retrospective analysis of HSC unrelated 
transplants performed in our center to analyze the effect of the donor KIR B status on the 
clinical-outcome. Our results showed a better overall survival-rate in the AML recipients, 
HLA mismatched with the donor, when the donor KIR B content status is Best/Better (37% 
vs 18% at three years P=0,028). Moreover, we observed that AML recipients, whose Donors 
KIR B status was Best/Better, had more incidence of aGvHD grade I and II than patients 
whose Donors KIR B status was Neutral (70% vs 26%) and also a lower rate of relapse (36% 
vs 58%) and a better Disease Free Survival-rate (58% vs 38% at three years P=0,1) because of 
a better GvL effect.
Keywords: UDHSCT, NK cells, donor KIR B status, AML, GvL effect
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1. Introduction
1.1. Hematopoietic stem cell transplantation (HSCT)
Hematopoietic stem cell transplantation (HSCT) has emerged as one of the most useful ther-
apeutic strategies in the treatment of hematologic malignancies (acute or chronic myeloid 
or lymphoid leukemia) or hereditary (Thalassemia major) for which conventional therapies 
offer little or no chance of cure. HSCT consists of the replacement of the diseased or non-
functional bone marrow with healthy stem cells capable of regenerating all blood cells and 
restoring the normal hematologic and immunologic functions. The source of hematopoietic 
stem cells (HSC) can be bone marrow (BMT), peripheral blood after appropriate stimula-
tion (PBHSCT) or cord blood (CBHSCT). The transplant can be autologous (the patient’s 
own HSC transplant after suitable treatment) or allogeneic (HSC transplant from a healthy 
donor). In the latter case, it is essential to find a donor with genetic characteristics similar to 
those of the receiver because one of the most important variables that influence the success of 
HSCT is the compatibility of the genes of the HLA system. The Class I and II HLA matching 
between donor and recipient is crucial to prevent alloreactivity and, consequently, rejection, 
graft failure and, above all, the graft versus host disease (GVHD), because the transplanted 
cells from the donor are immunologically competent and can attack cells and tissues of the 
recipient [1–3].
A very important aspect of the HSC transplant is the graft versus leukemia effect (GvL), which 
is a GvHD directed toward the leukemic cells: donors’ T lymphocytes attack the cells of the 
tissues causing GvHD but they can also attack and eliminate residual leukemic cells [4]. If the 
donor-recipient HLA compatibility is high, the GvL effect is low, consequently, the possibility 
of relapse is high; on the contrary, when the HLA compatibility is low, the GvHD reaction will 
be great. A major challenge in improving the success of allogeneic hematopoietic stem cells 
in the treatment of leukemia is to minimize GvH reactions and simultaneously preserve and 
optimize GvL reactions. It has also been demonstrated that the GvL effect may be mediated 
by NK cells [5].
It has been shown that only 25% of patients who need a HSC transplant find an HLA-identical 
sibling donor; the remaining 75% do not have an HLA-identical donor in their own family; in 
this case, the alternative is to look for a HLA-matched, unrelated volunteer donor (matched 
unrelated donor (MUD)) in the worldwide register of bone marrow donors. If there is no 
compatible donor, the choice of the haploidentical donor is a viable alternative, because there 
might often be half-identical donors such as parents or siblings [6]. Recently, the number 
of so-called alternative donor transplants, MUD and haploidentical transplants with one or 
more HLA mismatches has significantly increased. This is due to the rise in the average age of 
the patients and therefore the impossibility of finding a compatible donor in their own family. 
For this reason research has steered toward the study of factors other than HLA matching, 
which could have a positive influence on the outcome of the transplants, including the role of 
natural killer (NK) cells in hematopoietic stem cell transplants and, consequently, the study 
of killer-cell immunoglobulin-like receptors (KIRs) genes.
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1.2. Natural killer cells and KIRs
The human NK cells are a part of the immune system with an important role in the host’s 
defense against infections from pathogens and in “immune surveillance” against cancer cells. 
Their function depends on several families of activating and inhibitory receptors including 
KIR (killer-cell immunoglobulin-like receptors). The “missing-self” concept [7, 8], put for-
ward by Karré and colleagues in the 1980s, formed the basis for understanding the mecha-
nisms of the action of NK cells (Figure 1). According to this hypothesis, the function of NK 
cells is to recognize and kill autologous cells which are deficient in MHC Class I expression, a 
frequent event in tumor or virus-infected cells.
KIRs belong to the immunoglobulin superfamily and are structurally characterized by two or 
three extracellular immunoglobulin-like domains. KIRs recognize the MHC Class I molecules 
such as HLA-A, HLA-B and HLA-C. There are two distinct groups of KIRs: inhibitors and acti-
vators. The family of KIR genes, located on chromosome 19q13.4, includes 15 different loci [9]. 
Receptors are monomeric (single chain) with two (KIR2D) or three (KIR3D) immunoglobulin 
domains, which can be further divided into those with a long (Long) cytoplasmic tail (KIR2DL 
and KIR3DL) and those with a short (Short) one (KIR2DS and KIR3DS). The short tail gener-
ates an activation signal, while the long one generates an inhibition signal. Each group has the 
same extracellular domain, and consequently each group binds the same ligands. However, 
due to differences in their transmembrane and intracellular domains, a group of KIRs deter-
mines an inhibitory response, while the other group determines an activating response [10]. 
KIRs and their ligands are summarized in Table 1.
Figure 1. “Missing-self hypothesis” explains the mechanism of action of NK cells.
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In normal cells the expression of Major Histocompatibility Complex (MHC) Class I molecules 
and their binding to NK inhibitory receptors inhibits the lysis, while in the virus-infected 
or cancer cells the lack of expression of self MHC molecules determines their susceptibility 
to lysis mediated by NK cells. In tumor or virus-infected cells, stress-induced molecules are 
expressed on the cell surface and are recognized by the activating receptors that enhance the 
lysis. NK cells can also lyse allogeneic cells expressing HLA Class I antigens that are not rec-
ognized by their inhibitory NK receptors.
The KIR genes are polymorphic in humans and there are different allelic variants; each 
individual possesses his own KIRs repertoire depending on the allelic variants possessed. 
Different haplotypes contain a different number of KIR genes; some have only one or a 
few activating receptors, others have more activating receptors. In humans, two groups of 
KIR haplotypes have been identified, A and B, based on the content of different KIR genes. 
Haplotypes of group A are present in the entire population and consist of six KIR inhibitory 
genes KIR3DL3, KIR2DL3, KIR2DL1, KIR2DL4, KIR3DL1 and KIR3DL2 and one activator 
KIR2DS4 that is often present in a null allele variant that is not expressed on the cell surface. 
Group B comprises haplotypes with a different genetic content including genes KIR2DS2, 
KIR2DL2, KIR2DL5, KIR2DS3, KIR2DS1, KIR2DS5 and KIR3DS1 that are not part of the hap-
lotypes of Group A. As a consequence, many haplotypes in Group B encode for a greater 
number of activating receptors compared to haplotypes in Group A.
All individuals can be classified on the basis of the two KIR genotypes possessed: A/A, which is 
homozygous for the haplotypes of Group A, B/x, which contains one (heterozygous A/B) or two 
haplotypes of Group B (homozygous B/B). Individuals B/x possessing a larger number of activat-
ing receptors theoretically should have a better response against cancer or virus-infected cells.
KIRs KIR ligands
KIR2DL1 Group 2 HLA-C Asn77 Lys80 (w2, w4, w5, w6)
KIR2DS1
KIR2DL2 Group 1 HLA-C Ser77 Asn80 (w1, w3, w7, w8)
KIR2DL3
KIR2DS2
KIR3DL1 HLA-Bw4
KIR3DL2 HLA-A3,-A11
KIR2DL4 HLA-G
KIR2DL5 Unknown
KIR3DL7
KIR2DS4
KIR2DS5
KIR3DS1
Table 1. KIRs and their ligands.
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1.3. Role of NK Cells in HSCT
In recent years, the antileukemic potential of natural killer (NK) cells and their role in hema-
tologic malignancies and in HSCT has been attracting ever greater interest; however, it has 
not yet been clearly established whether the typing of KIR genes may be a useful tool in the 
selection of an HSC donor to promote a better outcome of the transplant [11].
The beneficial GvL effect, promoted by alloreactive NK cells derived from the donor, was 
demonstrated for the first time in the HSC haploidentical transplants in patients with acute 
myeloid leukemia (AML); the best donor is NK mismatched with the recipient and therefore 
the donor’s KIRs do not recognize HLA class I molecules expressed by the host. In this way, the 
donor’s NK cells are responsive to the direction GvH and this results in a better antileukemic 
effect with a better overall survival rate and a lower rate of relapse of leukemia [12].
More recently, Cooley et al. [13] have demonstrated that AML patients who received HSC 
transplants from unrelated Group B KIR haplotype donors had a better outcome after trans-
plant, whereas recipient KIR genotype had no effect. The clinical outcome was better when 
the donors had one or two KIR B haplotypes (KIR B/x donors) rather than donors who had 
two KIR A haplotypes (KIR A/A donors); with a KIR B/x donor, relapse was reduced and the 
leukemia-free survival rate (LFS) was increased. This is because the haplotypes of Group B 
have a larger number of activating receptors, and this translates into better antileukemic activ-
ity. A subsequent study [14] sought to determine whether the protective effect of KIR B could 
be mapped to either the centromeric or the telomeric region of the KIR locus. The centromeric 
region contains genes encoding the inhibitory receptors for the C1 and C2 epitopes of HLA-C, 
whereas the telomeric region contains genes encoding the inhibitory receptors for the Bw4 
and A3/11 epitopes and the activating C2 receptor. It was found that both the centromeric and 
telomeric regions of KIR B correlated with protective effect, but the much stronger associa-
tion was with the centromeric region. As a consequence of these results, an algorithm was 
formulated, called “KIR B-content score”, based on the number of centromeric and telomeric 
Group B KIR haplotypes gene-content motifs. The KIR B-content score defines three catego-
ries of donors: neutral donors have none or one KIR B motifs, better donors have two or more 
B motifs without KIR Cen B/B and best donors have two or more B motifs with KIR Cen B/B. 
A calculator for classification of the donor KIR B status (best, better and neutral) may be found 
at http://www.ebi.ac.uk/ipd/kir/.
Recently, these results have been confirmed in HSCT from HLA-identical sibling donor [15]. 
Together, these results highlight the need for further studies of KIR polymorphisms, possibly 
at allelic level, to determine whether the typing of the donor KIR genes may be useful in donor 
selection for HSCT.
2. Research aims
The aim of our research is a retrospective analysis of HSC transplants performed at the Bone 
Marrow Transplant Unit (UTMO) of the “V. Cervello” Hospital in Palermo. The category of 
HSC transplants to be studied is the one from MUD.
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The objectives of this study are the following:
1. Typing of the donors’ KIR genes of the transplants performed.
2. Donors classification in accordance with the KIR B Content Score in three categories: neutral, 
better and best.
3. Correlation of the donor KIR B status with the clinical outcome of the transplants considering 
overall survival, the degrees of graft versus host disease (GvHD) graft versus leukemia 
(GvL), relapse and disease-free survival (DFS).
3. Materials and methods
3.1. Patient cohort
We analyzed 89 patients, who received a URD HSCT between 1996 and 2013. The median age of 
the 89 patients was 43 years (14–65). The transplanted patients had different hematological malig-
nancies: 33 acute myeloid leukemia (AML), 19 acute limphoblastic leukemia (ALL), 9 myelo-
dysplastic syndromes (MDS), 6 non-Hodgkin lymphoma (NHL), 6 multiple myeloma (MM), 5 
Hodgkin lymphoma (HL), 4 chronic myeloid leukemia (CML), 3 chronic lymphocytic leukemia 
(CLL), 1 aplastic anemia syndrome (AAS), 1 Fanconi syndrome, 1 ematodermic neoplasia and 1 
biphenotypic acute leukemia (BAL). The HSC source was: bone marrow no. 19, peripheral blood 
no. 70. Complete high-resolution, allele-level HLA-A, B, C, DRB1 and DQB1 typing of the 89 pairs 
of recipients and donors was previously performed: 32 pairs were 10/10 matched, 33 pairs were 
9/10 and 24 were ≤8/10. Patient and transplant characteristics are summarized in Tables 2 and 3.
Median age (range) 43 (14–65)
Diagnosis
AML 33
ALL 19
MDS 9
NHL 6
MM 6
LH 5
CML 4
CLL 3
AAS 1
Fanconi syndrome 1
Ematodermic neoplasia 1
BAL 1
Table 2. Patient characteristics.
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3.2. KIR genotyping
The donors’ DNA that has already been typed for HLA has been preserved in our biobank; 
about 80% of the samples is still available. The DNA was extracted from buffy coat or whole 
blood by the automatic extractor Maxwell 16 (Promega) or by the salting out method.
Typing of KIR genes was performed with PCR-SSO Luminex, the same method already used 
in our laboratory to type the HLA genes. The kit used for KIR genes typing was the SSO KIR 
Genotyping Test (One Lambda Inc., Canoga Park, CA) and the method was performed in 
accordance with the manufacturer’s instructions. Luminex technology is based on the ability 
to soundly measure multiple analytes simultaneously in a single reaction and this is done 
through the use of plastic microbeads (microspheres), which are color-coded with two fluo-
rescent dyes so as to emit two different wave lengths in red and infrared. In this way a set of 
over 100 different microspheres can be created. The microspheres represent the solid support 
of oligonucleotide probes which can bind amplified DNA that is labeled with a fluorescent 
labeled reporter. Subsequently, the microbeads are acquired by the Luminex machine through 
a precision sheath fluid system, based on classical flow cytometry, which aligns them in single 
file, where they pass through two lasers: the red laser excites the colors inside the microbeads 
to identify which microbead is currently being read, while the green laser excites the color on 
the microbead surface, that is, the labeled reporter tag. Finally, the color signals are detected 
by an advanced optical system, and the signals are processed into data for each reaction [16].
Graft type
Bone marrow 19
Peripheral blood progenitor cells 70
Conditioning
Busilvex-ciclofosfamide 15
Busilvex-fludarabine 15
Fludarabine-melphalan 4
Thiotepa + others 7
Ciclofosfamide + others 14
Endoxan 4
Unknown 32
TBI 6
ATG 12
Donor/recipient HLA-allele matching at A, B, C, DRB1 and DQB1
10/10 32
9/10 33
≤8/10 24
Table 3. Transplants characteristics.
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The PCR using specific primers for the KIR genes is first conducted with a specific ampli-
fication program via the GeneAmp PCR System 9700 (Applied Biosystems, Forster City, 
CA). The amplification products are tested by electrophoresis on 2% agarose gel and then 
observed and photographed under a UV transilluminator. The PCR product is biotinylated, 
which allows it to be detected by strepavidin-conjugated with PE (SAPE). Subsequently, 
the PCR products are denatured facilitating rehybridization to complementary DNA probes 
bound to the microbeads with a specific sequence (SSO) to recognize the polymorphic sites 
within KIR genes. The amplified products which have undergone a hybridization reaction 
are labeled with streptavidin conjugated with R-Phycoerythrin and then acquired with the 
flow cytometry system LABScanTM 100 (Luminex), which measures the fluorescence inten-
sity of phycoerythrin on each microsphere. The data are then analyzed with the software 
HLA Fusion.
4. Results
4.1. Donor classification
We typed KIR genes of the 89 selected donors of the transplanted patients and we classified 
them on the basis of the KIR haplotypes possessed. KIR gene frequency among the donor 
population was similar to that of published data [17, 18]: no. 30 (33.7%) donors were A/A and 
no. 59 (66.3 %) were B/x.
Then we classified them using the donor KIR B Content Score Calculator at http://www.ebi.
ac.uk/ipd/kir/: no. 63 (70.8%) donors were neutral, no. 18 (20.2%) better and no. 8 (9%) best. In 
our analysis we combined the better and best groups to form the KIR better/best donor group 
(with two or more B motifs). The classification of the donors in accordance with the KIR B 
content score is summarized in Table 4.
Donor/
recipient 
HLA-
allele 
matching 
at A, B, 
C, DRB1 
and 
DQB1
Total
n = 89
AML recipients
n = 33
ALL recipients
n = 19
Other hematological 
malignancies
n = 37
Donor 
KIR B 
status
Donor 
KIR B 
status
Donor 
KIR B 
status
Donor 
KIR B 
status
Donor 
KIR B 
status
Donor 
KIR B 
status
Donor KIR 
B status
Donor KIR 
B status
Total 
(89)
Neutral 
(63)
Best/
better 
(26)
Tot (33) Neutral 
(21)
Best/
better 
(12)
Tot (19) Neutral 
(14)
Best/
better 
(5)
Tot (37) Neutral 
(28)
Best/better 
(9)
10/10 32 24 8 10 9 1 7 4 3 15 11 4
9/10 33 22 11 14 7 7 8 7 1 11 8 3
≤8/10 24 17 7 9 5 4 4 3 1 11 9 2
Table 4. Donor classification in accordance with the KIR B content score.
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4.2. Clinical outcome analysis
4.2.1. Overall survival, relapse and disease-free survival
The overall survival rate was analyzed generating the Kaplan-Meyer curves, using the 
GraphPad6 Demo software; the data were compared using the log-rank test 95%CI.
We observed no significant difference in the overall survival rate of those patients trans-
planted from A/A donor and those from B/x donor, while we found a better overall survival 
rate in the AML recipients, HLA mismatched with the donor, when the donor KIR B content 
status is best/better (37 vs. 18% at three years log-rank test P = 0.028) (Figure 2), whereas there 
is no beneficial effect in recipients with other hematological malignancies (Figure 3).
Figure 2. Overall survival rate of AML recipients of HLA mismatched MUD transplants.
Figure 3. Overall survival rate of recipients with other hematologic malignancies of HLA mismatched MUD transplants.
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Moreover, we observed that AML recipients, whose donor KIR B status was best/better, had 
a lower incidence of relapse than patients whose donor KIR B status was neutral (36 vs. 58%) 
(Figures 4 and 5) and a better disease-free survival rate (58 vs. 38% at three years P = 0.1) 
(Figure 6).
Figure 4. Incidence of relapse in AML recipients of best/better MUD.
Figure 5. Incidence of relapse in AML recipients of neutral MUD.
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We have not been able to make a comparison of the 10/10 HLA matched AML recipients 
because only one donor was best/better.
4.2.2. aGvHD
The incidence of aGvHD in AML patients was: 55.17% (no. 16/29) of no aGvHD, 41.38% 
(no. 12/29) of aGvHD grade I and II, 3.45% (no. 1/29) of aGvHD grade III and IV (Figure 7).
Figure 6. Disease-free survival rate of AML recipients of HLA mismatched MUD transplants.
Figure 7. The incidence of aGvHD in AML patients.
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We observed that AML recipients, whose donor KIR B status was best/better, had more inci-
dence of aGvHD grade I and II than patients whose donor KIR B status was neutral: 70 vs. 26% 
(Figures 8 and 9).
Actually, as regards patients who have aGvHD grade I and II, this results in a beneficial effect 
on the overall survival rate. In fact, we observed that patients with aGvHD grade I and II had a 
significantly better overall survival rate than patients with noGvHD (51.6 vs. 38% at three years 
P = 0.04) (Figure 10). This agrees with those studies [4] showing that patients with aGvHD I and 
II have a better overall survival rate and a lower rate of relapse due to a GvL effect.
Figure 8. Incidence of aGvHD in AML recipients of neutral MUD.
Figure 9. Incidence of aGvHD in AML recipients of best/better MUD.
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5. Discussion
In recent years, various studies have shown that the beneficial GvL effect promoted by allo-
reactive NK cells derived from the donor can improve the outcome of the HSCT from hap-
loidentical, unrelated and HLA identical sibling donors. In particular Cooley et al. [12] have 
demonstrated that AML patients who received HSC transplants from unrelated Group B 
KIR haplotypes donors, had a better outcome after transplant because the haplotypes of 
Group B have a larger number of activating receptors, and this translates into better anti-
leukemic activity. In a subsequent study [13], they found that some particular KIRs had 
a stronger effect and they defined three categories of donors: neutral (none or one KIR B 
motifs), better (two or more B motifs without KIR Cen B/B) and best (two or more B motifs 
with KIR Cen B/B).
In our study we analyzed the impact of the donor KIR B status on the outcome of the unrelated 
HSC transplants performed in our center. We observed no significant difference in overall 
survival of those patients transplanted from A/A donor and those from B/x donor, probably 
because we do not have a large enough cohort of transplanted patients, and we were not able 
to make a meaningful comparison; on the other hand, despite this small cohort of patients, we 
have been able to observe the powerful effect of the best/better donor KIR B status in the AML 
recipients HLA mismatched with the donor. They had a significantly better overall survival 
rate if the donor KIR B content status was best/better and they also had a higher incidence of 
aGvHD grade I and II, and had a lower rate of relapse due to GvL effects.
Even though our cohort was small, our results confirmed that the presence of more activator 
KIR genes in donors can improve the outcome of UDHSC HLA mismatched transplants in 
AML recipients whereas there is no benefit in recipients with other hematologic malignancies. 
Our next target is to increase the number of cases by adding the other transplants performed 
and to study the effect of GvL in relapse in the same patients.
Figure 10. Patients with aGvHD grade I and II had a significantly better overall survival rate than patients with noGvHD 
(51.6 vs. 38% at three years P = 0.04).
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In any case, our results confirm that NK cells derived from donors with two or more KIR B 
motifs have an improved ability to kill residual leukemic blasts in AML recipients of UDHSCT. 
As a consequence of this, the KIR genotype of the donor is another important criterion to be 
taken into account for the choice of the best possible donor in unrelated, sibling and haploi-
dentical HSC transplant settings, together with all the other important factors, such as HLA 
matching, CMV status, blood group, age and gender. Future studies should be aimed at finding 
the right alloreactive subsets among donor NK cell repertoires, opening up the possibility 
for successful NK cell–based immunotherapy. Antileukemic NK cells, either allogeneic or 
unlicensed autologous NK cells, emerge as a feasible therapy option and might improve the 
clinical outcome in myeloid leukemia.
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